print_label | resize_label





Prime device before first use.



Hold the inhaler in the upright position. Twist the brown grip fully in one direction as far as it will go.



Twist it fully back in the other direction as far as it will go. You will hear a "click" during one of the twisting movements.



Close your lips around the mouthpiece and inhale deeply and forcefully through the inhaler.


For additional information on how to use PULMICORT FLEXHALER, including how to prime, load, and clean the device, refer to the Patient Instructions for Use section of the full Prescribing Information.

WATCH THE VIDEO for detailed directions on how to use PULMICORT FLEXHALER.


  • Patients must prime their device before using for the first time (see full Prescribing Information for detailed instructions)
  • PULMICORT FLEXHALER will only give one dose at a time, no matter how often the brown grip is clicked, but the dose indicator will continue to move (advance). This means that if patients continue to move the brown grip, it is possible for the indicator to show fewer doses or zero doses even if more doses are left in their inhaler
  • Patients should not shake the inhaler after loading it
  • Patients may not sense the presence of the medication entering their lungs when inhaling from PULMICORT FLEXHALER. This does not mean they are not getting the medication. They should not repeat inhalations even if they do not feel the medication when inhaling
  • Patients should not blow or exhale into the mouthpiece
  • After taking a dose, patients should place the white cover back on the inhaler and twist it shut
  • Patients should rinse their mouth with water (but not swallow) after each dose to decrease the risk of getting thrush



1. PULMICORT FLEXHALER Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.


  • PULMICORT FLEXHALER is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT FLEXHALER because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.
  • Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients.
  • It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses.
  • Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.
  • Rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids.
  • Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.
  • PULMICORT FLEXHALER contains small amounts of lactose, which contains trace levels of milk proteins. In patients who have severe milk protein allergy (not those who are lactose intolerant) cough, wheezing, or bronchospasm may occur.
  • Adverse reactions that occurred at a rate of ≥ 1% are: nasopharyngitis, nasal congestion, pharyngitis, allergic rhinitis, viral upper respiratory tract infection, nausea, viral gastroenteritis, otitis media, and oral candidiasis.


  • PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age or older.

Please click here for full Prescribing Information for PULMICORT FLEXHALER.

You may report side effects related to AstraZeneca products by clicking here.